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Abstract 
 
Selecting a suitable sham condition within the frame of repetitive transcranial magnetic 
stimulation (rTMS) treatment trials is a central issue. On the one hand, the ideal sham condition 
should not have a real stimulation effect; on the other hand, it should not be recognized as sham by 
patients, particularly when considering that real stimulation conditions come along with rTMS 
specific side effects. Within the course of a multicentre trial assessing the antidepressant effects of 
rTMS, patients were randomized to sham or real stimulation, in both cases using a standard 
stimulation coil. In one centre, patients (n=33) were asked about their impression whether they 
received the sham or the real treatment, and if they would recommend the treatment to others. 29 
patients returned the questionnaires and were included into the analysis. From 15 subjects with real 
stimulation, 11 suggested to have obtained real, and 4 to have obtained sham. From 14 sham 
stimulated subjects, 9 suggested to have obtained the real condition and 5 to have been sham 
stimulated. This difference was not significant (p=0.60, chi square test). In addition, the major part 
of patients in both stimulation conditions would recommend rTMS to others. In both conditions, 
real and sham, the majority of subjects believed to have obtained the real condition. This implies 
suitability of the sham condition used since subjects appeared not to be able to identify the 
condition. The results imply the feasibility of a valid sham condition with a “real” coil.  
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Introduction 
Major depression belongs to the leading causes of disease burden worldwide [4]. Repetitive 
transcranial magnetic stimulation (rTMS) was introduced as a promising treatment option for 
depression and showed beneficial but at most moderate effects in single- and multi-centre trials [7, 
10, 11, 13, 18, 19]. Its application in depressed patients had recently been approved by the U.S. 
Food and Drug Administration and it is increasingly offered in psychiatric services. However, till 
now it remains difficult to draw consistent conclusions about the antidepressant efficacy of rTMS 
based on present publications. This is firstly due to inconsistent results, secondly due to 
methodological issues [8, 16, 19]. A primary issue, evident in each randomised stimulation trial, is 
the sham condition. On the one hand, real stimulation and sham stimulation have to be different 
concerning their efficacy: real should cause an effective stimulation, sham should not. On the other 
hand, sham and real should not differ concerning the subjective experience of the stimulation. The 
first aspect can be fulfilled by dislocating the coil or using a so called “sham coil”, the second one 
by inducing the characteristic noise and the sensory, sometimes painful artefact [5]. That sensory 
artefact however, is not present when using commercially available sham coils or it is of a different 
character when attempting to mimic the sensory impression [2]. Further, it is impossible to blind the 
experimenter because he or she has to apply the stimulation and has to know how and where to do 
that. The term “double-blind”, within rTMS trials, thus refers only to patient and rater, who are 
unaware of the stimulation condition. Still, the experimenter might have an unintentional influence 
on the patient. Since stimulation conditions have to be different between each other to establish 
sham and real, the patient, too, might identify the applied condition. Accordingly, in randomised 
controlled trials (RCTs) the question often arises whether patients are able to guess their treatment 
condition. In the present study we aimed to clarify whether patients participating an rTMS RCT 
would be able to successfully guess which kind of stimulation they received: sham or active. 
Additionally, we also considered interesting to know whether the patients believed to benefit from 
the stimulation and would recommend the stimulation to others, and whether their expectation 
towards the stimulation might have biased treatment outcome.  
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Methods 
Study design and participants 
Within the frame of a randomised, double-blind, placebo-controlled, multi-centre trial to assess 
the antidepressant effect of rTMS [11], the patients within one centre (Ulm, n=37, 4 drop-outs, 33 
completed the treatment trial, 29 of these returned the questionnaires, fig. 1), were asked in the 
weeks afterwards by a questionnaire about their experience of rTMS, particularly concerning the 
stimulation condition. All patients gave written informed consent. The trial was performed 
according to the latest version of the Declaration of Helsinki and was approved by the local ethics 
committee. Inclusion criteria were: age 18-75 years, a moderate or severe major depressive episode 
according to ICD-10 and DSM-IV and a score of 18 points or more in at least two of the three 
depression rating scales: Becks’ Depression Inventory (BDI) [3], Hamilton Depression Scale 
(HAM-D 21-items version) [9], Montgomery-Åsberg Depression Rating-Scale (MADRS) [17]. The 
detailed methodology with exclusion criteria and add-on design onto parallel established 
antidepressant medication and the clinical results of the trial were reported earlier [11]. Included 
patients were given an identification number linked to a centralised computer-generated 
randomisation code determining real or sham stimulation condition. 
 
Transcranial magnetic stimulation – real and sham condition 
A magnetic stimulator with a figure-of-eight coil was used for rTMS (Medtronic Magpro; 
Medtronic Inc., Minneapolis, MN, USA; coil: MC-B70). Patients were seated in a comfortable chair 
during stimulation. Stimulations were performed with a frequency of 10 Hz, trains of 2 seconds, 
inter-train-intervals of 8 seconds, 100 trains per session, 2000 stimuli per day on 15 subsequent 
working days. The real stimulation was applied above the left dorsolateral prefrontal cortex 
(DLPFC), targeted by guiding the coil to the position F3 according to the International 10-20 
system for electroencephalography electrode placement [12]. The real stimulation intensity was 
determined as 110% of the individual resting motor threshold (MT) [22]. Sham stimulation was 
applied 5 cm lateral to F3, perpendicular to the parasagittal plane, above the left temporal muscle. 
 4
To reduce a possible effectiveness of sham stimulation, the coil was angled at 45°, touching the 
skull not with the centre but with the rim opposite the handle, and the stimulation intensity was 
reduced to 90% MT. In this position, the coil-cortex distance also is essentially larger (more than 3 
cm versus 1-1.5 cm) than above F3, such that the electromagnetic field, if at all reaching the cortex, 
due to technical reasons was substantially weaker and far outside the target region.  
 
Questionnaires and statistics 
Within the weeks after the antidepressant stimulation, all patients that completed treatment in 
the centre should answer and return a questionnaire concerning their experience with rTMS, with a 
particular focus on the stimulation condition. If patients did not return the questionnaire upon the 
estimated time of four weeks, they were contacted by phone and asked the same questions. The 
following questions were posed (original in German, here English translation):  
a. Which expectation did you have concerning successful treatment prior to rTMS? Range 1 to 
4, with 1 being no, and 4 being very high expectations 
b. Two stimulation conditions were possible, real and sham, which one do you think you 
received? Sham/real 
c. Would you recommend rTMS treatment to others? Yes/no 
d. Did you have the impression that rTMS overall helped you? Yes/no 
Treatment outcome dependent on treatment conditions as measured with the three rating scales 
was analysed with Mann-Whitney U-test due to non-parametric distribution. In order to assess (i) 
whether the patients estimated to have received real or sham stimulation, (ii) whether they would 
recommend rTMS, and (iii) how they felt after rTMS, the data were analyzed with a chi square test. 
The hypothesis was that ‘real’ and ‘sham’ should not be discriminated by the patients as reflected in 
comparable amounts of estimations with no statistical differences concerning the questions of 
guessing the condition and of recommendation (assuming that one would not recommend a 
treatment not considered to be effective). To assess the influence of expectation on treatment 
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outcome irrespective of condition, we pooled the groups with low and medium low expectation vs. 
high and medium high expectation into two groups and subjected the data to a chi square test.  
 
Results 
From 37 patients that were enrolled in the centre, 33 completed stimulation. Within this group 
responses from 29 patients, i.e. 88%, were obtained, 4 patients did not answer (fig. 1). These 29 
were included in further analyses (demographic data in table 1). They responded to all questions 
except the question concerning recommendation which was not answered by 4 patients. Regarding 
the antidepressant treatment outcome, the patients did not show significant differences between real 
and sham in all three scales, whenever one might observe a descriptive improvement particularly of 
HAM-D and BDI scores (table 1). Concerning the HAM-D score, the sham group was slightly less 
depressed prior stimulation than the real group which was not the case in BDI and MAD.  
Regarding whether patients considered real to be real and sham to be sham, from 15 real 
stimulated patients, 11 suggested to have received real, and 4 sham. From 14 sham stimulated 
patients, 9 also estimated to have received the real condition and 5 to have been sham stimulated 
(table 1). This difference was not significant (p=0.60, chi square test). Further, the majority of 
patients in both stimulation conditions would recommend rTMS to others: 10 out of 15 ‘real’, and 9 
out of 14 ‘sham’ stimulated patients. Higher expectation towards rTMS concerning improvement of 
depression did not result in better treatment outcome than lower expectations (table 1).  
Finally regarding the question whether the patients had the subjective impression that rTMS 
was effective or not, 11 of the 15 real stimulated patients got this impression (73%), and 5 of the 
sham stimulated patients (36%), which represented a significant difference (p=0.042, chi square).  
 
Discussion 
Regarding the crucial issues of blinding in rTMS treatment trials and of using a control 
condition to test against the real one, the aim of the study was to assess whether patients that were 
randomized to real or sham stimulation in an antidepressant treatment trial would guess the applied 
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stimulation condition. The main finding was that patients did not identify the sham stimulation 
condition as such. In both groups a comparable majority of patients estimated the stimulation to be 
real. On the other hand, a considerable amount of patients in the real condition thought the 
condition to be ‘sham’. The result of non-identification of sham is also supported by the finding that 
the major part of patients would recommend rTMS as treatment strategy in depression, and this 
result was obtained irrespective of the stimulation condition. Concerning the clinical outcome as 
measured with the rating scales, no advantage in rTMS response was observed due to the ‘real’ 
condition apart a descriptive improvement. This is in line with the overall results of the multicentre 
trial [11]. However, and interestingly, when being asked whether they had the general impression of 
having benefited from rTMS, a majority of real stimulated patients had this impression but only a 
minority of the sham group. This is of course no hard criterion; nevertheless, it was significant and 
may be taken to indicate sort of a subjective effect. This points also to a less to a placebo effect of 
the sham condition, because in case of a placebo effect both groups should have had a comparable 
subjective effect of sham and real. However, with our add-on design comprising standardized 
medication, a statement on a possible placebo effect is difficult [6].  
Finding a valid sham condition in TMS research and particularly in RCTs is of key importance 
for producing valid outcomes [2, 14]. Considering the facts that the experimenter can not be blinded 
(unlike the rater) and the patients may either detect that they received an untypical stimulation 
because they are informed about TMS or because of less or no sensory side effects in relation to the 
sham stimulation, the probability of guessing the condition should be high. Several strategies have 
been proposed to address this issue. These can be divided in two principal strategies: First, by 
modifying a real stimulation in a way that it is ineffective (e.g. [11]), for instance by reducing the 
intensity, angling the coil or dislocating the coil. Secondly, it can be done by applying a special 
sham coil (e.g. [18]). In both strategies, the issue of the side effects of rTMS are to be considered. 
These are particularly the acoustic artefact and the local sensory artefact. The acoustic artefact is 
present in both strategies. The sensory artefact is not present or has to be technically simulated with 
the sham coil [5], or it might be critically diminished when modifying a real stimulation to be 
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ineffective. In our rTMS multi-centre trial, a modified stimulation condition for sham was chosen. 
We combined the three possibilities of angling and dislocating the coil and reducing the stimulation 
intensity. Whenever angling of the coil might be registered by the patients to be a different coil 
handling as when measuring the motor threshold, this was a compromise made for attempting to 
apply a sham condition largely similar to real but with as less as possible efficacy. Because of the 
dislocation towards direction of the temporal muscle, the coil-cortex distance was conceivably 
higher (>3cm concerning anatomical evaluation with frameless stereotaxic visualizing) than above 
the prefrontal cortex. Further, due to angling the focus of the magnetic field was not directed 
towards the skull but just in the air. Due to the resulting substantially weaker electromagnetic field 
that might have reached the cortex largely outside the target region in this condition compared to 
real rTMS, a possible neuronal depolarisation [14, 15] was unlikely, as was any possible 
antidepressant effect. Nevertheless, this kind of sham stimulation had disturbing effects by local 
sensations above the temporal muscle, which was directly touched with the rim of the coil, due to 
stimulation, that were similar to the disturbance caused by the real stimulation [1, 20]. Using a sham 
coil with no stimulation would have been even more different to real stimulation considering the 
lack of local sensations compared to the experience of motor threshold determination. Newer 
developments of devices that for instance provide a sensory artefact by electrical stimulation are not 
(yet) available for standard use and cannot reproduce the effects of  magnetic stimulation exactly [2, 
21]. Our findings suggest that the “real” coil with the described modifications can be used for a 
reliable and simply applicable sham condition in randomized rTMS trials, and they support the 
validity of the results from this methodological point of view.     
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Table 1: Demographic and clinical data of included patients. 
 
 Real Sham sign., p 
N 15 14  
Age m/sd 51.1 / 12.1 52.6 / 13.4 n.s. (0.74) 
Gender 7m / 8f 5m / 9f n.s. (0.36) 
BDI pre m/sd 29.9 / 9.4 32.0 / 7.3 n.s. (0.50) 
HAM pre m/sd 24.3 / 3.9 21.1 / 4.1 0.036 
MAD pre m/sd 29.1 /3.8 27.8 4.9 n.s. (0.43) 
BDI diff m/sd -14.9 / 9.2 -10.6 / 11.4 n.s. (0.25) 
HAM diff m/sd -13.7 / 7.5 -10.5 / 8.2 n.s. (0.29) 
MAD diff m/sd -16.5 / 7.8 -14.9 / 8.5 n.s. (0.91) 
Co venlafaxine 8 7 
Co mirtazapine 7 7 
 
n.s. (0.86) 
Consid. real n (%) 11 (73%) 9 (64%)  
Consid. sham n (%) 4 (27%) 5 (36%) 
 
n.s. (0.60) 
Recom. Yes n (%) 10 (67%) 9 (64%)  
Recom. no/miss. (%) 5 5 
 
n.s. (0.16) 
Benefit yes 11 (73%) 5 (36%) 
Benefit no 4 (27%) 9 (64%) 
 
0.042 
 
Abbreviations: m mean, sd standard deviation, diff difference pre-post, co co-medication, consid. 
consideration (question 1), recom. recommendation (question 2), miss. missings  
Statistics: t-test for age, Mann Whitney U test for rating data, Chi square test for categorical data.  
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Figure 
 
Figure 1 Diagram illustrating the inclusion of patients in questionnaire assessment.  
Completion of questionnaires 
and included in analysis n=29 
Sham n=15 
Real n=14 
Completed rTMS trial and 
included for questionnaires 
n=33 
Drop-out in course 
of treatment n=4 
No return of 
questionnaires n=4 
Included in local 
rTMS trial n=37 
 13
